abs226.txt	the	2013	update	of	the	american	society	of	clinical	oncology-college	of	americanpathologists	(asco-cap)	human	epidermal	growth	factor	receptor	2	(her2)	testingguidelines	recommend	using	an	alternative	chromosome	17	probe	assay	to	resolveher2	results	determined	to	be	equivocal	by	immunohistochemistry	(ihc)	orfluorescence	in-situ	hybridization	(fish)		however		it	is	unclear	if	casesconsidered	her2-positive	(her2+)	by	the	alternative	probe	method	are	similar	tothose	classified	as	her2+	by	traditional	ihc	and	fish	criteria	and	benefit	thesame	from	her2-targeted	therapies		we	studied	the	clinical	and	pathologicfeatures	of	all	31	breast	cancers	classified	as	her2+	by	the	alternative	probemethod	at	our	institution	since	2013	and	determined	their	pam50	intrinsicmolecular	subtypes		for	comparison		we	analyzed	19	consecutive	cases	that	wereclassified	as	her2+	by	traditional	fish	criteria	during	the	same	time	period	thirty	(97%)	cancers	in	the	alternative	probe	cohort	were	estrogen	receptor(er)-positive	(er+)		while	only	9/19	(47%)	of	traditional	her2	controls	were	er+(p	=	0	0002)		sufficient	tissue	for	intrinsic	subtype	analysis	was	available	for20/31	cancers	in	the	alternative	probe	cohort	and	9/19	in	the	traditional	her2+group		none	(0%)	of	the	20	alternative	probe-positive	cases	were	of	theher2-enriched	intrinsic	subtype		while	8/9	(89%)	of	those	her2+	by	traditionalfish	criteria	were	her2-enriched	(p	=	0	0001)		these	findings	suggest	that	breastcancers	classified	as	her2+	only	by	the	alternative	probe	method	are	biologicallydistinct	from	those	classified	as	her2+	by	traditional	criteria		and	raisesquestions	as	to	whether	or	not	they	derive	the	same	benefit	from	her2-targetedtherapies	
